Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms-Reference-Cited by-同舟云学术

Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms

Published:2013-05-23 Issue:21 Volume:121 Page:4388-4395
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Rumi Elisa¹²,Pietra Daniela²,Guglielmelli Paola³,Bordoni Roberta⁴,Casetti Ilaria¹,Milanesi Chiara²,Sant’Antonio Emanuela¹,Ferretti Virginia²,Pancrazzi Alessandro³,Rotunno Giada³,Severgnini Marco⁴,Pietrelli Alessandro⁴,Astori Cesare²,Fugazza Elena²,Pascutto Cristiana²,Boveri Emanuela⁵,Passamonti Francesco⁶,De Bellis Gianluca⁴,Vannucchi Alessandro³,Cazzola Mario¹²

Affiliation:

1. Department of Molecular Medicine, University of Pavia, Pavia, Italy;

2. Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy;

3. Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy;

4. Institute for Biomedical Technologies, National Research Council of Italy, Segrate, Italy;

5. Anatomic Pathology Section, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; and

6. Division of Hematology, Department of Internal Medicine, Ospedale di Circolo e Fondazione Macchi, Varese, Italy

Abstract

Key Points In MPL exon 10–mutated myeloproliferative neoplasms, the MPL-mutant allele burden varies considerably from about 1% to almost 100%. High mutation burdens originate from acquired copy-neutral loss of heterozygosity of chromosome 1p and are associated with marrow fibrosis.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/121/21/4388/1366333/4388.pdf

Reference42 articles.

1. The myeloproliferative disorders.;Campbell;N Engl J Med,2006

2. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.;Baxter;Lancet,2005

3. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.;Levine;Cancer Cell,2005

4. A gain-of-function mutation of JAK2 in myeloproliferative disorders.;Kralovics;N Engl J Med,2005

5. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.;James;Nature,2005

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Detecting Multiple Driver Mutations in a Patient with Essential Thrombocythemia;American Journal of Case Reports;2023-12-23

2. Molecular diagnostic criteria of myeloproliferative neoplasms;Expert Review of Molecular Diagnostics;2023-11-24

3. Genomics of clonal evolution in a rare essential thrombocythemia with coexisting Type 2 CALR and MPL S204P mutations;Platelets;2023-02-14

4. Clinical Application of Biomarkers for Hematologic Malignancies;Biomarkers in Medicine;2022-08-30

5. A CRISPR/Cas9 engineered MplS504N mouse model recapitulates human myelofibrosis;Leukemia;2022-08-23